# Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

> **NCT00572637** · PHASE1 · COMPLETED · sponsor: **Ethical Oncology Science** · enrollment: 55 (estimated)

## Conditions studied

- Solid Tumors
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** CEP-18770

## Key facts

- **NCT ID:** NCT00572637
- **Lead sponsor:** Ethical Oncology Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2010-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572637, "Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00572637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*